Michelle Bolyard, NP
Gerontology · Lagrange, INNPI 1316370018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 26.0% of the total. Reporting peaked in 2023 at $1,065 and has fallen 78.0% since, to $234 in 2025.
Across 105 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$819
- AstraZeneca$777
- Boehringer Ingelheim$249
- GSK$203
- Regeneron Healthcare Solutions, Inc.$184
- Sanofi$157
- plus $759 from 19 others
What the payments were for
- Travel & lodging$2889%
- Food & beverage$2,86091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 14 | $819 |
| AstraZeneca | 22 | $777 |
| Boehringer Ingelheim | 5 | $249 |
| GSK | 9 | $203 |
| Regeneron Healthcare Solutions, Inc. | 7 | $184 |
| Sanofi | 8 | $157 |
| Inogen, Inc. | 4 | $80 |
| Electromed, Inc. | 5 | $72 |
| Baxter Healthcare | 2 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Mylan Specialty L.p. | 4 | $61 |
| Amgen | 3 | $47 |
| Insmed, Inc. | 3 | $47 |
| United Therapeutics Corporation | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $43 |
| Covis Pharma GmbH | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Abbott | 1 | $27 |
| Grifols USA, LLC | 1 | $27 |
| Harmony Biosciences LLC | 1 | $27 |
| Bayer | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,148 in reported general payments places this provider in the 85th percentile of 230 gerontology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 595 | $591,374 |
| Dupixent PenDupilumab | 25 | $109,337 |
| Breo ElliptaFluticasone/Vilanterol | 169 | $106,271 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $64,358 |
| Spiriva RespimatTiotropium Bromide | 52 | $43,404 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $39,567 |
| EliquisApixaban | 22 | $29,283 |
| Advair HfaFluticasone Propion/Salmeterol | 54 | $24,774 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $24,220 |
| Arnuity ElliptaFluticasone Furoate | 52 | $23,129 |
| Spiriva HandihalerTiotropium Bromide | 24 | $21,277 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $19,277 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $17,847 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $14,803 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 456 | $12,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $203 | $779,618911 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $777 | $88,578135 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $249 | $69,58696 claims |
| MerckDulera | $16 | $5,87712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 230 gerontology providers in Indiana.
Other gerontology in Lagrange
- Angela PattiMunster$44K
- Jessica KiszkaMunster$42K
- Sandra GarofaloIndianapolis$24K
- Megan MonnierBloomington$23K
- Diane BrackinFishers$13K
- Karie BeasleyEvansville$13K
- Mary ParkerFort Wayne$13K
- Morgan SlawsonMunster$9K
- Marena ArnoldFort Wayne$8K
- Beau SemlerDanville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.